AUA 2018: Onabotulinumtoxina Injection to the External Urethral Sphincter for Voiding Dysfunction in Females

San Francisco, CA (UroToday.com) The treatment options for voiding dysfunction in females, especially in the case of urinary retention, are limited. Management typically defaults to the use of catheterization to empty the bladder, either at regular intervals or continuously, in order to prevent long-term sequelae to the upper urinary tract. 

Mariele Trimboli, MD, along with her group at the University College London Hospital, examined the potential role of onabotulinumtoxinA injections into the external urethral sphincter (EUS) for the treatment of female voiding dysfunction during.

At their tertiary care center, injection of 100 units of onabotulinumtoxinA into the EUS was performed in selected females from 2015 to 2017, all under general anesthesia. All patients were evaluated with pre-operative videourodynamic studies and urethral pressure profilometries (UPP).  Following treatment, all had three months of follow up.

During this time frame, 10 female patients with a mean age 45.5 years (18-80 years) underwent onabotulinumtoxinA injections into the EUS. Four had urodynamic evidence of bladder outflow obstruction, of which two had detrusor sphincter dyssynergia. Six patients were noted to have an acontractile detrusor as a contributing cause for their retention. The mean pre-operative mid-urethral closure pressure (MUCP) was 93.3 cm H20 (mean expected MUCP was 45 cm H2O), with eight patients having elevated MUCP values preoperatively.

UroToday_AUA2018_OnabotulinumtoxinA injection to the external urethral sphincterFigure 1: OnabotulinumtoxinA injection to the external urethral sphincter


Prior to intervention with botox into the UES, 4 women were voiding, 4 were performing clean intermittent self-catherization, and 2 had indwelling suprapubic catheters to empty their bladders. 6 had failed previous treatments with sacral nerve stimulation. 

Following onabotulinumtoxinA injections, 6 were voiding, 2 continued performing CISC, and 2 remained with suprapubic catheters. Median pre-operative QMax values improved from 8.5 ml/s to 12.5 ml/s, and mean post void residual volume decreased from 244 ml to 94 ml. 4 patients reported quality of life improvement after treatment, although 1 reported short lived benefit lasting less than 3 months. 2 patients went onto repeat treatments, of which one patient complained of transient stress urinary incontinence after repeat injection. There were no significant adverse events in all patients.

The authors concluded that onabotulinumtoxinA treatment to the EUS is a safe and potentially valid treatment in selected females with voiding dysfunction, in whom therapeutic options are limited. Efficacy may be short lived, however, and further study with longer follow-up is warranted.



Presented by: Mariele Trimboli, MD, University  College  London  Hospitals 

Co-Authors: Seth Jai, Sarah  Itam, Eabhann O'Connor, Rizwan Hamid, Jeremy Ockrim, Tamsin Greenwell, Mahreen Pakzad, London, United Kingdom 

Written by:  Judy Choi, MD, Assistant Professor, Department of Urology, University of California, Irvine @judymchoi at the 2018 AUA Annual Meeting - May 18 - 21, 2018 – San Francisco, CA USA
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe